Hematopoietic growth factors

Pharmaceutical Biotechnology: Fundamentals and Applications, Third Edition

Volumn , Issue , 2016, Pages 225-242

  Foote, MaryAnn ^a  

^a MaryAnne Foote Associates   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84903800392     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (83)

1. Abels RL, Larholt KM, Krantz KDA, Bryant EC (1991). Recombinant human erythropoietin (r-HuEPO) for the treatment of the anemia of cancer. In: Murphy MJ, ed. Blood Cell Growth Factors. Dayton, OH: Alpha Med Press, 121-41.
2. Armitage JO (1998). Emerging applications of recombinant human granulocyte colony-stimulating factor. Blood 92:4491-508.
3. Brandwein JM, Nayar R, Baker MA, et al. (1991). GM-CSF therapy for delayed engraftment after autologous bone marrow transplantation. Exp Hematol 19:191-5.
4. Broudy VC (1997). Stem cell factor and hematopoiesis. Blood 90:1345-64.
5. Broudy VC, Lin NL, Sabath DF, Papayannopoulou T, Kaushansky K (1997). Human platelets display highaffinity receptors for thrombopoietins. Blood 89:1896-904.
6. Casadevall N, Nataf J, Viron B, et al. (2002). Pure red-cell aplasia and anti-erythropoietin antibodies in patients treated with recombinant erythropoietin. New Eng J Med 346:469-75.
7. Catlin DH, Hatton CK, Lasne F (2003). Abuse of recombinant erythropoietins by athletes. In: Molineux G, Foote MA, Elliott SG, eds. Erythropoitins and Erythropoiesis. Molecular, Cellular, Preclinicall, and Clinical Biology. Basel, Switzerland: Birkhauser, 205-27.
8. Cebon I, Layton JE, Maher D, Morstyn G (1994). Endogenous haemopoietic growth factors in neutropenia and infection. Br J Haematol 86:265-74.
9. Chevallier B, Chollet P, Merrouche Y, et al. (1995). Lenograstim prevents morbidity from intensive induction chemotherapy in the treatment of inflammatory breast cancer. J Clin Onc 13:1564-71.
10. Colgan SP, Gasper PW, Thrall MA, Boone TC, Blancquaert AMB, Bruyninckx WJ (1992). Neutrophil function in normal and Chediak-Higashi syndrome cats following administration of recombinant canine granulocyte colony-stimulating factor. Exp Hematol 20:1229-34.
11. Crawford J, Ozer H, Stoller R, et al. (1991). Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. New Eng J Med 325:164-70.
12. Dale DC, Bonilla MA, Davis MW, Nakanishi AM, Hammond WP, Kurtzberg J, et al. (1993). A randomized controlled phase III trial of recombinant human granulocyte colony-stimulating factor (filgrastim) for treatment of severe chronic neutropenia. Blood 81:2496-502.
13. Dale DC, Liles WC, Llewellyn C, Price TH (1998). Effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) on neutrophil kinetics and function in normal human volunteers. Am J Hematol 57:7-15.
14. Du XX, Williams DA (1997). lnterleukin-11: Review of molecular, cell biology, and clinical use. Blood 89:3897-908.
15. Egrie JC, Dwyer E, Browne JK, Hitz A, Lykos M (2003). Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. Exp Hematol 31:290-9.
16. Elliott S, Egrie J, Browne J, et al. (2004). Control of rHuEPO biological activity: The role of carbohydrate. Exp Hematol 32:1146-55.
17. Elliott S, Heatherington AC, Foote MA (2004). Erythropoietic factors. In: Morstyn G, Foote MA, Lieschke GJ, eds. Hematopoietic Growth Factors in Oncology: Basic Science and Clinical Therapeutics. Totowa, NJ: Humana Press, 97-123.
18. Erslev AJ (1991). Erythropoietin. New Eng J Med 324:1339-44.
19. Eschbach JW, Abdulhadi MH, Browne JK, et al. (1989). Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter trial. Ann Int Med 111:992-1000.
20. Fischl M, Galpin JE, Levine JD, et al. (1990). Recombinant human erythropoietin for patients with AIDS treated with zidovudine. New Eng J Med 322:1488-93.
21. Galli SJ, Zsebo KM, Geissler EM (1994). The kit ligand, SCF. Adv Immunol 55:1-96.
22. Gerhartz HH, Englehard M, Meusers P, et al. (1993). Randomized, double-blind, placebo-controlled, phase III study of recombinant human granulocyte-macrophage colony-stimulating factor as adjunct to induction treatment of high-grade malignant non-Hodgkin's lymphomas. Blood 82:2329-39.
23. Gerson SK, Luksenburg H, Cote TR, Braun MM (2002). Pure red-cell aplasia and recombinant erythropoietin. New Eng J Med 346:1584-6.
24. Gisselbrecht C, Prentice HG, Bacligalupo A, et al. (1994). Placebo-controlled phase III trial of lenograstim in bone marrow transplantation. Lancet 343:696-700.
25. Glaspy JA, Shpall EJ, LeMaistre CF, et al. (1995). Peripheral blood progenitor cell mobilization utilizing stem cell factor in combination with filgrastim in breast cancer patients. Blood 90:2939-51.
26. Glaspy JA, Jadeja JS, Justice G, et al. (2002). Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy. Br J Cancer 87:268-76.
27. Green MD, Koelbl H, Baselga J, et al. (2003). A randomized double-blind multicenter phase II study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 14:29-35.
28. Grichnik JM, Crawford J, Jiminez F, et al. (1995). Human recombinant stem-cell factor induces melanocytic hyperplasia in susceptible patients. J Am Acad Dermatol 33:577-83.
29. Gronski P, Badziong W, Habermann P, et al. (1988). Escherichia coli derived human granulocyte-macrophage colony-stimulating factor (rh GM-CSF) available for clinical trials. Behring Inst Mitteilungen 83:246-9.
30. Groopman JE, Molina JM, Scadden DT (1989). Hematopoietic growth factors. Biology and clinical applications. New Eng J Med 321:1449-59.
31. Hart D (1997). Dendritic cells: Unique leukocyte populations which control the primary immune response. Blood 90:3245-87.
32. Hartung T, Doecke WD, Bundschuh D, et al. (1999). Effect of filgrastim treatment on inflammatory cytokines and lymphocyte functions. Clin Pharmacol Ther 66:415-24.
33. Henke M, Laszig R, Rube C, et al. (2003). Erythropoietin used to treat head and neck cancer patients with anemia undergoing radiotherapy: Randomised, double- blind, placebo-controlled trial. Lancet 362:1255-60.
34. Holmes FA, O'Shaughnessy JA, Vukelja S, et al. (2002). Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol 20:727-31.
35. Jacobson JO, Goldwasser E, Fried W, Plzak L (2000). Role of the kidney in erythropoiesis. J Am Soc Nephrol 11:589-92.
36. Johnston E, Crawford J, Blackwell S, et al. (2000). Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy. J Clin Oncol 18:2522-28.
37. Kaushansky K (1995). Thrombopoietin: Basic biology, clinical promise. Int J Hematol 62:7-15.
38. Kauchansky K (2005). The molecular mechanisms that control thrombopoiesis. J Clin Inv 115:3339-47.
39. Klingemann HG, Eaves AC, Barnett MJ, et al. (1990). Recombinant GM-CSF in patients with poor graft function after bone marrow transplantation. Clin Inv Med 13:77-81.
40. Kuritzkes DR, Parenti D, Ward D, et al. (1998). Filgrastim prevents severe neutropenia and reduces infective morbidity in patients with advanced HIV infection:results of a randomized, multicenter, controlled trial. AIDS 12:65-74.
41. Kuter DJ, Hunt P, Sheridan W, Zucker-Franklin D, eds. (1994a). Thromobopoiesis and Thrombopoeitin. Totowa, NJ: Humana Press, 412.
42. Kuter DJ, Beeler DL, Rosenberg RD (1994b). The purification of megapoietin: A physiological regulator of megakaryocyte growth and platelet production. Proc Natl Acad Sci USA 91:11104-8.
43. Kuter DJ (1997). The regulation of platelet production in vivo. In: Kuter DJ, Hunt P, Sheridan W, Zucker-Franklin D, eds. Thrombopoiesis and Thrombopoietins. Totowa, NJ: Humana Press, 377-97.
44. Lacerna L, Sheridan WP, Basser R, et al. (2000). Stem cell factor. In: Ho AD, Haas R, Champlin RE, eds. Hematopoietic Stem Cell Transplantation. New York:Marcel Dekker, 31-46.
45. Lane TA, Law P, Maruyama M, et al. (1995). Harvesting and enrichment of hematopoietic progenitor cells mobilized into the peripheral blood of normal donors by granulocyte-macrophage colony-stimulating factor (GM-CSF) or G-CSF: potential role in allogeneic marrow transplantation. Blood 25:275-82.
46. Langley KE (2004). Stem cell factor and its receptor, c-Kit. In:Morstyn G, Foote MA, Lieschke GJ, eds. Hematopoietic Growth Factors in Oncology. Totowa, NJ: Humana Press 153-84.
47. Langley KE, Bennett LG, Wypych J, et al. (1993). Soluble stem cell factor in human serum. Blood 81:656-60.
48. Leyland-Jones B, Mahmud S (2004). Erythropoietin to treat anaemia in patients with head and neck cancer. Lancet 363:80.
49. Lieschke GJ, Grail D, Hodgson G, et al. (1994). Mice lacking granulocyte colony-stimulating factor have chronic neutropenia, granulocyte and macrophage progenitor cell deficiency, and impaired neutrophil mobilization. Blood 84:1737-46.
50. Lok S, Kaushansky K, Holly RD, et al. (1994). Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo. Nature 369:565-8.
51. Lord BI, Bronchud MH, Owens S, et al. (1989). The kinetics of human granulopoiesis following treatment with granulocyte colony-stimulating factor in vivo. Proc Natl Acad Sci USA 86:9499-503.
52. Lord BI, Gurney H, Chang J, Thatcher N, Crowther D, Dexter TM (1992). Haemopoietic cell kinetics in humans treated with rGM-CSF. Int J Cancer 50:26-31.
53. Macdougall IC, Gray SJ, Elston O, et al. (1999). Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol 10:2392-5.
54. Markham A, Bryson HM (1995). Epoetin alpha. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in nonrenal applications. Drugs 49:232-54.
55. Metcalf D (1990). The colony stimulating factors. Discovery, development, and clinical applications. Cancer 65:2185-95.
56. Miles SA, Mitsuyasu RT, Moreno J, et al. (1991). Combined therapy with recombinant granulocyte colony-stimulating factor and erythropoietin decreases hematologic toxicity from zidovudine. Blood 77:2109-17.
57. Molineux G (2004). The design and development of pegfilgrastim (PEG-rmetHuG-CSF, Neulasta). Curr Pharmaceut Design, 10:1235-44.
58. Molineux G, Foote MA, Elliott SG (2003). Erythropoietins and Erythropoiesis: Molecular, Cellular, Preclinical, and Clinical Biology. Basel, Switzerland: Birkhasuer, 269.
59. Nagata S, Tsuchiya M, Asano S, et al. (1986). Molecular cloning and expression of cDNA for human granulocyte- colony stimulating factor. Nature 319:415-8.
60. Nemunaitis J, Rabinowe SN, Singer JW, et al. (1991). Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer. New Eng J Med 324:1773-78.
61. Nichol JL, Hokom MM, Hornkohl A, et al. (1995). Megakaryocyte growth and development factor. Analyses of in vitro effects on human megakaryopoiesis and endogenous serum levels during chemotherapy- induced thrombocytopenia. J Clin Invest 95:2973-8.
62. Orazi A, Cooper RJ, Tong J, et al. (1996). Effects of recombinant IL-11 (Neumega rhlL-11 growth factor) on megakaryocytopoiesis in human bone marrow. Exp Hematol 24:1289-97.
63. Rapoport AP, Abboud CN, DiPersio JF (1992). Granulocyte macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF):Receptor biology, signal transduction, and neutrophil activation. Blood Rev 6:43-57.
64. Roskos LK, Cheung EN, Vincent M, Foote MA, Morstyn G (1998). Pharmacology of filgrastim (r-metHuG-CSF). In: Morstyn G, Dexter TM, Foote MA, eds. Filgrastim (r-metHuG-CSF) in Clinical Practice. New York:Marcel Dekker, 51-71.
65. Rowe JM, Andersen JW, Mazza JJ, et al. (1995). A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia: A study of the Eastern Cooperative Oncology Group (E1490). Blood 86:457-62.
66. Schmitz N, Dreger P, Zander AR, et al. (1995). Results of a randomised, controlled, multicentre study of recombinant human granulocyte colony-stimulating factor (filgrastim) in patients with Hodgkin's disease and non-Hodgkin's lymphoma undergoing autologous bone marrow transplantation. Bone Marrow Transpl 15:261-6.
67. Schmitz N, Linch DC, Dreger P, et al. (1996). Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet 10:353-7.
68. Shpall EJ, Wheeler CA, Turner SA, et al. (1999). A randomized phase 3 study of peripheral blood progenitor cell mobilization with stem cell factor and filgrastim in high-risk breast cancer patients. Blood 93:2491-501.
69. Sheridan WP, Begley CG, Juttner CA, et al. (1992). Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy. Lancet 339:640-4.
70. Siena S, Nicola M, Mortorini R, Anichini A, Bregni M, Parmiani G, Gianni AM (1997). Expansion of immunostimulatory dendritic cells from peripheral blood of patients with cancer. Oncologist 2:65-9.
71. Souyri M, Vigon I, Penciolelli J-F, Tambourin P, Wendling F (1990). A putative truncated cytokine receptor gene transduced by the myeloproliferative leukemia virus immortalizes hematopoietic progenitors. Cell 63:1137-47.
72. Souza LM, Boone TC, Gabrilove J, et al. (1986). Recombinant human granulocyte colony-stimulating factor: Effects on normal and leukemic myeloid cells. Science 232:61-5.
73. Stahel RA, Jost LM, Cerny T, et al. (1994). Randomized study of recombinant human granulocyte colony-stimulating factor after high-dose chemotherapy and autologous bone marrow transplantation for high-risk lymphoid malignancies. J Clin Oncol 12:1931-8.
74. Stanley E, Lieschke GJ, Grail D, et al. (1994). Granulocyte/ macrophage colony-stimulating factor-deficient mice show no perturbation of hematopoiesis but develop a characteristic pulmonary pathology. Proc Natl Acad Sci USA 91:5592-6.
75. Tepler I, Elias L, Smith JW, et al. (1996). A randomized placebo-controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy. Blood 87:3607-14.
76. Trillet-Lenoir V, Green J, Manegold C, et al. (1993). Recombinant granulocyte colony stimulating factor reduces infectious complications of cytotoxic chemotherapy. Eur J Cancer 29A:319-24.
77. Vansteenkiste J, Pirker R, Massuti B, et al. (2002). Doubleblind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Nat Cancer Inst 94:1211-20.
78. Veys N, Vanholder, R, Lameire N (1992). Pain at the injection site of subcutaneously administered erythropoietin in maintenance hemodialysis patients: A comparison of two brands of erythropoietin. Am J Nephrol 12:68-72.
79. Vigon I, Mornon JP, Cocault L, et al. (1992). Molecular cloning and characterization of MPL, the human homolog of the v-mpl oncogene: Identification of a member of the HGF receptor superfamily. Proc Natl Acad Sci USA 89:5640-4.
80. Weaver C, Schulman K, Wilson-Relyea B, Birch R, West W, Buchner CD (2000). Randomized trial of filgrastim, sargramostim, or sequential sargramostim and filgrastim after myelosuppressive chemotherapy for the harvesting of peripheral-blood stem cells. J Clin Oncol 18:43-53.
81. Weisbart RH, Golde DW (1989). Physiology of granulocyte and macrophage colony-stimulating factors in host defense. Hematol Oncol Clin North Am 3:401-9.
82. Welte K, Gabrilove J, Bronchud MJ, Platzer E, Morstyn G (1996). Filgrastim (r-metHuG-CSF): The first 10 years. Blood 88:1907-29.
83. Winter JN, Lazarus HM, Rademaker A, et al. (1996). Phase I/II study of combined granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor administration for the mobilization of hematopoietic progenitor cells. J Clin Oncol 14:277-86.